Mesothelioma Web logo

 

Clinical Trials at Dana-Farber/Harvard Cancer Center


Phase II Trial of MTA Administered Intravenously Every 21 Days in Patients With Malignant Pleural Mesothelioma (offered at Dana-Farber Cancer Institute, Brigham & Women's Hospital and Massachusetts General Hospital)

Phase I Trial of Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin and Intravenous Sodium Thiosulphate in the Multimodality Treatment of Malignant Pleural Mesothelioma (offered at Dana-Farber Cancer Institute and Brigham & Women's Hospital)

Phase I Trial of Extrapleural Pneumonectomy Followed by Intrathoracic/Intraperitoneal Heated Cisplatin and Intravenous Sodium Thiosulfate in the Multimodality Treatment of Malignant Pleural Mesothelioma (offered at Dana-Farber Cancer Institute and Brigham & Women's Hospital)

Phase II Study of Capecitabine in Patients With Malignant Mesothelioma


Back to Comprehensive Cancer Centers